[조사자료] 글로벌 재조합 단백질 치료제 CDMO 시장 (2023-2030) : 성장 호르몬, 인터페론, 백신, 면역 자극제

■ 영문 제목 : Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents), By Source, By Indication, By Region, And Segment Forecasts, 2023 - 2030
	■ 상품코드 : GRV23NOV236 ■ 조사/발행회사 : Grand View Research ■ 발행일 : 2023년 9월 ■ 페이지수 : 175 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (납기:3일) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의료 기기

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD5,950 ⇒환산￦8,032,500	견적의뢰/주문/질문
Multi User (5인 열람용)	USD6,950 ⇒환산￦9,382,500	견적의뢰/주문/질문
Global/corporate License (기업 열람용)	USD8,950 ⇒환산￦12,082,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 재조합 단백질 치료제 CDMO 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 재조합 단백질 치료제 CDMO 시장 규모는 2030년까지 519억 5000만 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 13. 9%의 CAGR을 기록할 것으로 전망됩니다. 만성 질환의 유병률 증가, 생명 공학의 발전, 개인 맞춤형 의료의 부상, 생물의학 연구개발 투자 증가가 시장 성장의 주요 요인으로 꼽히고 있습니다.

재조합 단백질 치료제에 대한 수요가 증가함에 따라 바이오 의약품 제조 인프라 및 시설에 대한 투자가 증가하고 있습니다. 여기에는 대규모 생산 시설 설립, 공정 최적화, 제조 기술 개선 등이 포함됩니다. 생산 능력의 확대는 재조합 단백질 치료제의 생산량을 증가시켜 시장 성장을 촉진할 것으로 보입니다.

바이오 제약기업이 자체적으로 재조합 단백질 치료제을 개발하는 것은 시간과 자원이 많이 소요되며, CDMO에 아웃소싱을 통해 기업은 최첨단 시설, 전문 지식, 최적화된 공정을 이용할 수 있어 시간과 비용의 효율성을 높일 수 있습니다. CDMO는 역량을 확장하고 빠른 납기를 제공할 수 있기 때문에, 바이오제약 기업은 제품을 더 빨리 시장에 출시할 수 있습니다.

코로나19 팬데믹은 시장에 큰 영향을 미쳤으며, 코로나19 치료제와 백신에 대한 수요로 인해 재조합 단백질 치료제의 생산 능력이 확대되었습니다. 재조합 단백질 치료제 개발에 주력하고 있는 일부 기업들은 코로나19 관련 제품의 요구 사항을 충족하기 위해 공정 및 시설 규모를 확대했습니다. 이러한 확장은 코로나19 치료제 및 백신 생산을 강화할 뿐만 아니라 재조합 단백질 치료제 CDMO 산업의 투자 및 성장 기회를 창출했습니다. 예를 들어, 2021년 2월 GSK와 사노피는 보조 재조합 단백질 코로나19 백신 후보를 평가하기 위한 임상 2상 시험의 시작을 발표했습니다.

재조합 단백질 치료제 CDMO 시장 보고서 하이라이트

- 2022년 인터페론 분야가 21. 6%로 가장 큰 점유율을 차지했습니다. 만성 질환 및 감염성 질환 치료에 대한 재조합 단백질 인터페론에 대한 수요 증가가 이 부문을 주도하고 있습니다.

- 공급원 기준으로는 포유류 부문이 2022년 67. 3%로 가장 큰 점유율을 차지했습니다. 이 부문이 높은 점유율을 보이는 주된 이유는 포유류 유래 치료제의 외주 비중이 증가하고 있기 때문입니다.

- 종양학 부문은 예측 기간 동안 14. 8%의 가장 빠른 CAGR을 기록할 것으로 예상됩니다. 이는 암 치료에서 새로운 항체를 발견하기 위한 임상 시험의 비율이 증가하고 있기 때문입니다.

- 아시아 태평양 지역은 예측 기간 동안 14. 3%의 CAGR을 기록할 것으로 예상됩니다. 인도, 중국 등 아시아 국가들은 유럽과 미국에 비해 상대적으로 낮은 생산 비용으로 인해 이 지역 전체에서 더 많은 고객층을 끌어들여 이 지역의 성장을 견인하고 있습니다.

■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변동, 동향, 범위
Chapter 4. 세계의 재조합 단백질 치료제 CDMO 시장 : 유형별 예측 및 동향 분석
Chapter 5. 세계의 재조합 단백질 치료제 CDMO 시장 : 공급원별 예측 및 동향 분석
Chapter 6. 세계의 재조합 단백질 치료제 CDMO 시장 : 질환별 예측 및 동향 분석
Chapter 7. 세계의 재조합 단백질 치료제 CDMO 시장 : 지역별 예측 및 동향 분석
Chapter 8. 경쟁 현황

■ 보고서 목차

Table of Content

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Type
1.1.3. Source
1.1.4. Indication
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective – 1
1.4.2. Objective – 2
1.4.3. Objective – 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Recombinant Protein Therapeutics CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Recombinant Protein Therapeutics
3.2.1.2. Rising Adoption of Biologics and Biosimilars
3.2.1.3. Technological Innovations Pertaining to the Development of Novel Recombinant Protein Therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory Hurdles
3.2.2.2. Challenges Related to Quality Control
3.3. Recombinant Protein Therapeutics CDMO Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis
4.1. Recombinant Protein Therapeutics CDMO Market, By Type: Segment Dashboard
4.2. Recombinant Protein Therapeutics CDMO Market, By Type: Movement Analysis
4.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Type, 2018 – 2030
4.3.1. Growth Hormones
4.3.1.1. Growth Hormones Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.2. Interferons
4.3.2.1. Interferons Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.3. Vaccines
4.3.3.1. Vaccines Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.4. Immunostimulating Agents
4.3.4.1. Immunostimulating Agents Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.5. Others
4.3.5.1. Others Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis
5.1. Recombinant Protein Therapeutics CDMO Market, By Source: Segment Dashboard
5.2. Recombinant Protein Therapeutics CDMO Market, By Source: Movement Analysis
5.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Source, 2018 – 2030
5.3.1. Mammalian Systems
5.3.1.1. Mammalian Systems Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
5.3.2. Microbial Systems
5.3.2.1. Microbial Systems Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
5.3.3. Others
5.3.3.1. Others Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis
6.1. Recombinant Protein Therapeutics CDMO Market, By Indication: Segment Dashboard
6.2. Recombinant Protein Therapeutics CDMO Market, By Indication: Movement Analysis
6.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Indication, 2018 – 2030
6.3.1. Oncology
6.3.1.1. Oncology Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.2. Infectious Diseases
6.3.2.1. Infectious Diseases Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.3. Immunological Disorders
6.3.3.1. Immunological Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.4. Metabolic Disorders
6.3.4.1. Metabolic Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.5. Haematological Disorders
6.3.5.1. Haematological Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2022 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 – 2030 (Revenue, USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2018 – 2030
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2018 – 2030
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. UK Market Estimates and Forecasts, 2018 – 2030
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Germany Market Estimates and Forecasts, 2018 – 2030
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. France Market Estimates and Forecasts, 2018 – 2030
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Italy Market Estimates and Forecasts, 2018 – 2030
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Spain Market Estimates and Forecasts, 2018 – 2030
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 – 2030
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 – 2030
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Norway Market Estimates and Forecasts, 2018 – 2030
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. Japan Market Estimates and Forecasts, 2018 – 2030
7.6.2. India
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. India Market Estimates and Forecasts, 2018 – 2030
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2018 – 2030
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. South Korea Market Estimates and Forecasts, 2018 – 2030
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2018 – 2030
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 – 2030
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Brazil Market Estimates and Forecasts, 2018 – 2030
7.7.2. Mexico
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Mexico Market Estimates and Forecasts, 2018 – 2030
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 – 2030
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. South Africa Market Estimates and Forecasts, 2018 – 2030
7.8.2. Saudi Arabia
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 – 2030
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. UAE Market Estimates and Forecasts, 2018 – 2030
7.8.4. Kuwait
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 – 2030
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2022
8.2. Company Profiles
8.2.1. Richter-Helm BioLogics
8.2.1.1. Company Overview
8.2.1.2. Financial Performance
8.2.1.3. Service Benchmarking
8.2.1.4. Strategic Initiatives
8.2.2. Lonza
8.2.2.1. Company Overview
8.2.2.2. Financial Performance
8.2.2.3. Service Benchmarking
8.2.2.4. Strategic Initiatives
8.2.3. Catalent, Inc
8.2.3.1. Company Overview
8.2.3.2. Financial Performance
8.2.3.3. Service Benchmarking
8.2.3.4. Strategic Initiatives
8.2.4. FUJIFILM Diosynth Biotechnologies
8.2.4.1. Company Overview
8.2.4.2. Financial Performance
8.2.4.3. Service Benchmarking
8.2.4.4. Strategic Initiatives
8.2.5. WuXi Biologics
8.2.5.1. Company Overview
8.2.5.2. Financial Performance
8.2.5.3. Service Benchmarking
8.2.5.4. Strategic Initiatives
8.2.6. Curia Global, Inc.
8.2.6.1. Company Overview
8.2.6.2. Financial Performance
8.2.6.3. Service Benchmarking
8.2.6.4. Strategic Initiatives
8.2.7. Batavia Biosciences B.V.
8.2.7.1. Company Overview
8.2.7.2. Financial Performance
8.2.7.3. Service Benchmarking
8.2.7.4. Strategic Initiatives
8.2.8. HALIX B.V.
8.2.8.1. Company Overview
8.2.8.2. Financial Performance
8.2.8.3. Service Benchmarking
8.2.8.4. Strategic Initiatives
8.2.9. AGC Biologics
8.2.9.1. Company Overview
8.2.9.2. Financial Performance
8.2.9.3. Service Benchmarking
8.2.9.4. Strategic Initiatives
8.2.10. Enzene Biosciences
8.2.10.1. Company Overview
8.2.10.2. Financial Performance
8.2.10.3. Service Benchmarking
8.2.10.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 4 North America Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 5 North America Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 6 North America Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 9 U.S. Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 10 Canada Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 11 Canada Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 12 Canada Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 13 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 14 Europe Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 15 Europe Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 16 Europe Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 17 U.K. Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 18 U.K. Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 19 U.K. Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 20 Germany Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 21 Germany Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 22 Germany Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 23 France Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 24 France Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 25 France Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 26 Italy Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 27 Italy Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 28 Italy Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 29 Spain Recombinant Protein Therapeutics CDMO market, by Source type, 2018 - 2030 (USD Million)
Table 30 Spain Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 31 Spain Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 34 Denmark Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 37 Sweden Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 38 Norway Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 39 Norway Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 40 Norway Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 45 China Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 46 China Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 47 China Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 48 Japan Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 49 Japan Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 50 Japan Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 51 India Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 52 India Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 53 India Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 54 Australia Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 55 Australia Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 56 Australia Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 57 South Korea Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 58 South Korea Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 60 Thailand Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 61 Thailand Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 62 Thailand Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 65 Latin America Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 66 Latin America Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 68 Brazil Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 69 Brazil Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 71 Mexico Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 72 Mexico Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 74 Argentina Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 75 Argentina Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 79 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 81 South Africa Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 82 South Africa Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 86 UAE Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 87 UAE Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 88 UAE Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 90 Kuwait Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 91 Kuwait Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)

※본 조사보고서 [글로벌 재조합 단백질 치료제 CDMO 시장 (2023-2030) : 성장 호르몬, 인터페론, 백신, 면역 자극제] (코드 : GRV23NOV236) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 재조합 단백질 치료제 CDMO 시장 (2023-2030) : 성장 호르몬, 인터페론, 백신, 면역 자극제] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 첨단 치료제 CDMO 시장 (2023-2030) : 유전자 치료, 세포 요법, 조직 공학
GRV23MA018 / Grand View Research / 2023년 1월 / 미국 Grand View Research (그랜드뷰리서치)는 세계의 첨단 치료제 CDMO 시장 규모가 2023년부터 2030년 사이에 연평균 18.8% 성장하여, 2030년에는 188억 달러에 달할 것으로 예측하고 있습니다. 본 조사 자료는 세계의 첨단 치료제...Advanced Therapy Medicinal Products CDMO Market Growth & Trends The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.8% from 2023 to...

글로벌 핵산 치료제 CDMO 시장 (2023-2030) : 프로세스 개발 및 최적화, 제조 서비스
GRV23NOV219 / Grand View Research / 2023년 9월 / 글로벌 핵산 치료제 CDMO 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 핵산 치료제 CDMO 시장 규모는 2023년부터 2030년까지 연평균 9. 4%의 성장률을 보이며 2030년에는 224억 2000만 달러에...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 핵산 치료제 CDMO 시장 : 유형별 예측 및 동향 분석 Chapter 5. 세계의 핵산 치료제 CDMO 시장 : 서비스별 예측 및 동향 분석 Chapter 6. 세계의 핵산 치료제 CDMO 시장 : 최종...

세계의 저분자 이노베이터 API CDMO 시장 2024-2030 : 전임상, 임상, 상업용
GRV24MAY092 / Grand View Research / 2024년 4월 / 글로벌 저분자 이노베이터 API CDMO시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 저분자 이노베이터 API CDMO 시장 규모는 2024년부터 2030년까지 연평균 6. 53% 성장하여 2030년까지 471억 4000만...1. 조사 방법 및 범위 2. 개요 3. 세계의 저분자 이노베이터 API CDMO 시장 변수, 동향 및 범위 4. 세계의 저분자 이노베이터 API CDMO 시장 단계별 예측 및 동향 분석 5. 세계의 저분자 이노베이터 API CDMO 시장 고객 유형별 예측 및 동향 분석 6. 세계의 저분자 이노베이터 API CDMO 시장...

글로벌 원료 의약품 CDMO 시장 (2023-2030) : 강력한 API, 항체 약물 접합체
GRV23NOV025 / Grand View Research / 2023년 9월 / 글로벌 원료 의약품 CDMO 시장의 성장 및 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 원료 의약품 CDMO 시장 규모는 2030년까지 1,563억 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 연평균 6....Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변수/동향/범위 Chapter 4. 세계의 원료 의약품 CDMO 시장 : 제품별 분석 Chapter 5. 세계의 원료 의약품 CDMO 시장 : 합성별 분석 Chapter 6. 세계의 원료 의약품 CDMO 시장 : 약물별 분석 Chapter 7. 세계의 원료 의약품 CDMO 시장...

세계의 저분자 이노베이터 CDMO 시장 (2023~2030) : 저분자 원료 의약품, 저분자 의약품 제품
GRV23MR035 / Grand View Research / 2023년 2월 / 미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 저분자 이노베이터 CDMO 시장 규모가 2023년부터 2030년 사이에 CAGR 6.4% 증가하여, 2030년에는 749억 달러에 이를 것으로 전망하고 있습니다. 본 자료는 세계의...Small Molecule Innovator CDMO Market Growth & Trends The global small molecule innovator CDMO market size is expected to reach USD 74.9 billion by 2030, expanding at 6.4% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. There is a growing interest among pharmaceutical...